Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Extends Deadline for CombiMatrix to Meet Listing Requirement

NEW YORK (GenomeWeb News) – Nasdaq has granted CombiMatrix an extension to provide evidence that it is in compliance with a listing requirement, the company said in a regulatory document on Thursday.

In a filing with the US Securities and Exchange Commission, CombiMatrix said that Nasdaq has given it until Aug. 20 to provide evidence in its Form 10-Q for the second quarter ending June 30 that it complies with a rule calling for at least $2.5 million in stockholders' equity in order to remain listed on the exchange.

Nasdaq notified CombiMatrix it was not in compliance with the listing requirement in March and gave the firm until April 25 to submit a plan to regain compliance. The Irvine, Calif.-based firm submitted its plan and on May 22 it received notification from Nasdaq of the extension, it said.

If it fails to provide evidence, CombiMatrix could be subject to delisting. If notified by Nasdaq of such action, the company could appeal Nasdaq's determination to a listing qualifications panel.

According to CombiMatrix's Form 10-Q for the first quarter, as of March 31 it had stockholder equity totaling $2.1 million, up from a deficit of $1.1 million as of Dec. 31, 2012.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.